Why is GLP-1 coverage the hardest line on the renewal?
Every employer we talk to is having a version of the same meeting. Someone pulls up the pharmacy report, points at the GLP-1 line, and asks whether the plan can keep paying for it.
It is a fair question, but it is the wrong first one. Before you keep, cut or redesign GLP-1 coverage for 2027, you need to know what you are looking at. The numbers circulating in the market describe very different employers, and using the wrong benchmark is how good companies make expensive decisions.
GLP-1 drugs moved from a narrow diabetes therapy to a broadly requested benefit in a few years, faster than most plan designs could adapt. Many employers added weight-loss coverage when use was low. Then use caught up.
The International Foundation of Employee Benefit Plans (IFEBP) has tracked GLP-1 coverage since October 2023. In its 2026 survey report, respondents said GLP-1 drugs accounted for 11.4% of annual claims, up from 6.9% in 2023.
Large employers are feeling it in their coverage plans. In a Business Group on Health survey of 105 large employers, completed in February and March 2026, 67% covered GLP-1s for weight management. Of those, 72% expected to keep that coverage in 2027, 10% expected to drop it and 18% were unsure. The unsure group is the one to watch. Those employers know the status quo is not working and have not yet found a version of coverage they can defend.
Which benchmark fits your plan?
You have probably seen several numbers for how many employers cover GLP-1s for weight loss. They can all be right, because they count different companies.
| Source | Who was counted | Weight-loss coverage |
|---|---|---|
| KFF 2025 Employer Health Benefits Survey | Firms with 200 to 999 workers | 16% |
| KFF 2025 Employer Health Benefits Survey | Firms with 1,000 to 4,999 workers | 30% |
| KFF 2025 Employer Health Benefits Survey | Firms with 5,000 or more workers | 43%, up from 28% in 2024 |
| IFEBP 2026 survey | U.S. plan sponsors | 36% cover both diabetes and weight loss |
| Business Group on Health 2026 survey | 105 large employers | 67% |
The KFF survey shows the split clearly. If you employ 300 people and someone tells you “most employers cover these,” they are quoting a large-employer number. Pick the benchmark that matches your size, funding arrangement and industry. Our employee benefits trends for 2027 page tracks the KFF figures, including how often larger firms reported higher than expected use.
Is coverage still a yes or no decision?
Not anymore. IFEBP found that 60% of employers cover GLP-1s for diabetes only, 36% cover both diabetes and weight loss, and 45% cover them for other FDA-approved conditions such as sleep apnea and cardiovascular disease. The same plan often says yes for one indication and no for another.
That changes how you frame the decision internally. You are not voting the drug class up or down. You are drawing a line around indications, eligibility and duration, and then defending where you drew it.
IFEBP also found other approaches gaining ground. 27% of employers point employees to a direct-to-consumer platform, and 21% encourage them to use an FSA, HSA or integrated HRA for GLP-1 costs.
How did Medicare change the comparison?
CMS launched the Medicare GLP-1 Bridge on July 1, 2026. Eligible Part D enrollees can get certain GLP-1 drugs for weight management for $50 a month, and the program runs through December 31, 2027. According to CMS’s guidance for Part D plans, participating manufacturers supply the drugs at a net price of $245 per monthly supply.
Separately, Novo Nordisk announced a lower U.S. list price of $675 a month for Wegovy, Ozempic and Rybelsus starting January 1, 2027, and the FDA has approved an oral version of Wegovy.
A federal program now buys these drugs at a published net price. Your employees and your CFO can find that number.
The Bridge does not change your plan directly. It does make the gap visible. If your plan pays well above that net price, the question becomes one of transparency, and you need a clear answer on what your plan actually pays.
Which three numbers should drive the decision?
1. Your eligible population, not your current users. Modeling coverage on who fills prescriptions today understates the exposure. Apply your proposed eligibility rules to your own diagnosis and biometric data, then build three uptake scenarios: conservative, expected and high. Price each against your net cost per fill and see which ones the budget survives. Reversing coverage later does far more damage to trust than declining to add it.
2. How long members stay on the drug. A cohort study of 125,474 adults starting GLP-1 drugs found that 64.8% of patients without type 2 diabetes stopped within a year, compared with 46.5% of those with diabetes. High discontinuation lowers near-term spend. It also means much of what the plan spent may have bought little lasting benefit. A strategy that ignores persistence pays for starts, not outcomes.
3. Net cost per fill, not list price. What matters is your cost after rebates, and whether those rebates reach your plan. Employers in Peterson-KFF focus groups described rebates getting worse as a reason they dropped weight-loss coverage. If you cannot get a clean answer on net cost per fill, that is a contract problem, and it reaches well beyond one drug class. Our guide on how to choose a PBM covers the contract terms that decide what you can see.
What plan designs are employers using?
Four approaches cover most of the market. None is right for every plan. What matters is whether you can explain why you chose yours.
| Design | How it works | Tradeoff |
|---|---|---|
| Exclude weight loss | Cover GLP-1s for diabetes and other approved conditions, exclude weight management | Predictable cost, but you decline a therapy employees want and can see other plans covering |
| Clinical criteria | Require objective eligibility, prior authorization, a lifestyle program and continuation criteria tied to measured progress | The strongest middle path when administered honestly, not as a soft denial |
| Cost-share redesign | Move GLP-1s to a dedicated tier with higher member cost share or an annual maximum | Caps plan exposure, but affordability barriers fall hardest on those most likely to benefit |
| Transparent pharmacy arrangement | Move the category to a pass-through arrangement with full claims visibility | You see what you pay, but it takes contract work and a vendor change |
The last option is where a pharmacy benefits administrator model can help, because you can see the price paid for every fill and hold someone accountable for it. Ethos Benefits works through these designs with employers as part of its pharmacy and PBM work, starting from the plan’s own claims.
What does prudence require of the plan sponsor?
When GLP-1 coverage becomes purely a budget conversation, the fiduciary question gets lost. As a plan fiduciary, you are not required to cover every drug employees want, and you are not required to cut cost at any expense. You are required to make prudent, documented decisions in the interest of participants, using real data, through a process you could explain to a regulator or a plaintiff’s attorney.
A defensible GLP-1 decision has four parts:
- You analyzed your own claims and eligible population rather than borrowing a benchmark.
- You evaluated more than one design.
- You knew what the plan pays net of rebates.
- You wrote down why you chose what you chose.
An indefensible decision looks like this: the broker described what the market is doing, the committee approved it, and there is no record of the analysis.
There is a second obligation, and employees feel it most. However you decide, your people need to understand the rule before they need to use it. Unclear plan language, prior authorization criteria nobody can find and appeals that wear people down all lead to the same place: employees give up on care they were entitled to. If you use clinical criteria, publish them in plain language, tell people what documentation they need, and make sure your service team can walk someone through it. Employee communications belong in the plan before the decision is final.
How should you work the decision before renewal?
If your plan year starts January 1, you have weeks, not months. A workable sequence:
- Pull two years of pharmacy claims by indication, not just by drug name. Diabetes, weight management and other approved conditions behave differently and should be decided separately.
- Measure persistence. What share of members who started a GLP-1 last year are still filling at month twelve?
- Get your net cost per fill in writing. If your vendor cannot or will not produce it, you have learned something more important than the number.
- Model three designs against your own population, not one.
- Decide how you will communicate before you decide coverage. If you are narrowing coverage, employees should hear it from you early, with the reasoning and the alternatives.
- Document the process. Minutes, data reviewed, options considered and the reasoning. A material reduction in covered services also triggers a summary of material modifications under 29 CFR 2520.104b-3, so update the summary plan description work plan too.
Owning the pharmacy data is what made the difference for Kalos Services, which cut its pharmacy cost per member per month by 70% after changing its PBM arrangement. The Kalos Services case study shows how.
What is the bottom line?
GLP-1 drugs are not a passing trend, and they are not a line you can quietly delete. They work for many people, they cost a great deal, and the market around them is moving fast enough that a decision built on 2025 assumptions is already dated. Federal PBM reform will give plans more pharmacy data over the next few years, but the 2027 decision has to be made with what you can get now.
The employers handling this well stopped treating GLP-1 coverage as a yes or no vote and started treating it as a design problem with real data behind it. That is harder work, and it is the only version of the decision you can stand behind twelve months from now.
This article is general information, not legal, tax, medical or clinical advice. Review coverage decisions with counsel and clinical advisors. Figures reflect published sources as of October 27, 2026.